Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases

Josie L. Falany, Daniel E. Pilloff, Thomas S. Leyh, Charles N. Falany

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Raloxifene and 4-hydroxytamoxifen (4-OHT) are important estrogen-related drugs used in the treatment of osteoporosis and breast cancer. Sulfation is involved in the metabolism and inactivation of both compounds in human tissues, although the sulfotransferase (SULT) isoforms involved in their conjugation have not been well described. The ability of seven expressed SULT isoforms to sulfate raloxifene and 4-OHT was investigated. Raloxifene was conjugated by all seven SULT isoforms tested, whereas 4-OHT was conjugated only by SULTs 1A1, 1E1, and 2A1. Characterization of raloxifene and 4-OHT sulfation demonstrates that sulfation can occur at therapeutic concentrations. SULT1E1 displayed the lowest Km (0.2 μM) for 4-OHT sulfation and SULT2A1 the lowest (0.3 μM) for raloxifene sulfation. SULT1E1 was the only isoform exhibiting detectable levels of raloxifene disulfation activity. Modeling of the interactions of raloxifene in the active site of SULT1E1 indicates that both hydroxyl groups of raloxifene can be readily positioned in proximity to the sulfonyl group of 3′-phosphoadenosine 5′-phosphosulfate and the catalytically important His107 residue. Both raloxifene and 4-OHT sulfation activities were detectable in all human liver cytosols tested. 4-OHT sulfation was detected in cytosol prepared from endometrial biopsies of normal women obtained during the proliferative and secretory phases of the same menstrual cycle. In contrast, raloxifene sulfation was detectable only in secretory phase cytosols in association with SULT1E1 activity. In summary, several human SULT isoforms are capable of sulfating raloxifene and 4-OHT. Tissue-specific expression of the individual SULT isoforms may have important roles in the regulation of the activity of these compounds.

Original languageEnglish (US)
Pages (from-to)361-368
Number of pages8
JournalDrug Metabolism and Disposition
Volume34
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Sulfotransferases
Protein Isoforms
Cytosol
Raloxifene Hydrochloride
afimoxifene
Phosphoadenosine Phosphosulfate
Tissue
4,17 beta-dihydroxy-4-androstene-3-one
Biopsy
Luteal Phase
Metabolism
Hydroxyl Radical
Liver
Sulfates
Osteoporosis
Catalytic Domain
Estrogens

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. / Falany, Josie L.; Pilloff, Daniel E.; Leyh, Thomas S.; Falany, Charles N.

In: Drug Metabolism and Disposition, Vol. 34, No. 3, 03.2006, p. 361-368.

Research output: Contribution to journalArticle

Falany, Josie L. ; Pilloff, Daniel E. ; Leyh, Thomas S. ; Falany, Charles N. / Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. In: Drug Metabolism and Disposition. 2006 ; Vol. 34, No. 3. pp. 361-368.
@article{0b727483602d4b6c847b756e5a89d50a,
title = "Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases",
abstract = "Raloxifene and 4-hydroxytamoxifen (4-OHT) are important estrogen-related drugs used in the treatment of osteoporosis and breast cancer. Sulfation is involved in the metabolism and inactivation of both compounds in human tissues, although the sulfotransferase (SULT) isoforms involved in their conjugation have not been well described. The ability of seven expressed SULT isoforms to sulfate raloxifene and 4-OHT was investigated. Raloxifene was conjugated by all seven SULT isoforms tested, whereas 4-OHT was conjugated only by SULTs 1A1, 1E1, and 2A1. Characterization of raloxifene and 4-OHT sulfation demonstrates that sulfation can occur at therapeutic concentrations. SULT1E1 displayed the lowest Km (0.2 μM) for 4-OHT sulfation and SULT2A1 the lowest (0.3 μM) for raloxifene sulfation. SULT1E1 was the only isoform exhibiting detectable levels of raloxifene disulfation activity. Modeling of the interactions of raloxifene in the active site of SULT1E1 indicates that both hydroxyl groups of raloxifene can be readily positioned in proximity to the sulfonyl group of 3′-phosphoadenosine 5′-phosphosulfate and the catalytically important His107 residue. Both raloxifene and 4-OHT sulfation activities were detectable in all human liver cytosols tested. 4-OHT sulfation was detected in cytosol prepared from endometrial biopsies of normal women obtained during the proliferative and secretory phases of the same menstrual cycle. In contrast, raloxifene sulfation was detectable only in secretory phase cytosols in association with SULT1E1 activity. In summary, several human SULT isoforms are capable of sulfating raloxifene and 4-OHT. Tissue-specific expression of the individual SULT isoforms may have important roles in the regulation of the activity of these compounds.",
author = "Falany, {Josie L.} and Pilloff, {Daniel E.} and Leyh, {Thomas S.} and Falany, {Charles N.}",
year = "2006",
month = "3",
doi = "10.1124/dmd.105.006551",
language = "English (US)",
volume = "34",
pages = "361--368",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases

AU - Falany, Josie L.

AU - Pilloff, Daniel E.

AU - Leyh, Thomas S.

AU - Falany, Charles N.

PY - 2006/3

Y1 - 2006/3

N2 - Raloxifene and 4-hydroxytamoxifen (4-OHT) are important estrogen-related drugs used in the treatment of osteoporosis and breast cancer. Sulfation is involved in the metabolism and inactivation of both compounds in human tissues, although the sulfotransferase (SULT) isoforms involved in their conjugation have not been well described. The ability of seven expressed SULT isoforms to sulfate raloxifene and 4-OHT was investigated. Raloxifene was conjugated by all seven SULT isoforms tested, whereas 4-OHT was conjugated only by SULTs 1A1, 1E1, and 2A1. Characterization of raloxifene and 4-OHT sulfation demonstrates that sulfation can occur at therapeutic concentrations. SULT1E1 displayed the lowest Km (0.2 μM) for 4-OHT sulfation and SULT2A1 the lowest (0.3 μM) for raloxifene sulfation. SULT1E1 was the only isoform exhibiting detectable levels of raloxifene disulfation activity. Modeling of the interactions of raloxifene in the active site of SULT1E1 indicates that both hydroxyl groups of raloxifene can be readily positioned in proximity to the sulfonyl group of 3′-phosphoadenosine 5′-phosphosulfate and the catalytically important His107 residue. Both raloxifene and 4-OHT sulfation activities were detectable in all human liver cytosols tested. 4-OHT sulfation was detected in cytosol prepared from endometrial biopsies of normal women obtained during the proliferative and secretory phases of the same menstrual cycle. In contrast, raloxifene sulfation was detectable only in secretory phase cytosols in association with SULT1E1 activity. In summary, several human SULT isoforms are capable of sulfating raloxifene and 4-OHT. Tissue-specific expression of the individual SULT isoforms may have important roles in the regulation of the activity of these compounds.

AB - Raloxifene and 4-hydroxytamoxifen (4-OHT) are important estrogen-related drugs used in the treatment of osteoporosis and breast cancer. Sulfation is involved in the metabolism and inactivation of both compounds in human tissues, although the sulfotransferase (SULT) isoforms involved in their conjugation have not been well described. The ability of seven expressed SULT isoforms to sulfate raloxifene and 4-OHT was investigated. Raloxifene was conjugated by all seven SULT isoforms tested, whereas 4-OHT was conjugated only by SULTs 1A1, 1E1, and 2A1. Characterization of raloxifene and 4-OHT sulfation demonstrates that sulfation can occur at therapeutic concentrations. SULT1E1 displayed the lowest Km (0.2 μM) for 4-OHT sulfation and SULT2A1 the lowest (0.3 μM) for raloxifene sulfation. SULT1E1 was the only isoform exhibiting detectable levels of raloxifene disulfation activity. Modeling of the interactions of raloxifene in the active site of SULT1E1 indicates that both hydroxyl groups of raloxifene can be readily positioned in proximity to the sulfonyl group of 3′-phosphoadenosine 5′-phosphosulfate and the catalytically important His107 residue. Both raloxifene and 4-OHT sulfation activities were detectable in all human liver cytosols tested. 4-OHT sulfation was detected in cytosol prepared from endometrial biopsies of normal women obtained during the proliferative and secretory phases of the same menstrual cycle. In contrast, raloxifene sulfation was detectable only in secretory phase cytosols in association with SULT1E1 activity. In summary, several human SULT isoforms are capable of sulfating raloxifene and 4-OHT. Tissue-specific expression of the individual SULT isoforms may have important roles in the regulation of the activity of these compounds.

UR - http://www.scopus.com/inward/record.url?scp=33344467530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344467530&partnerID=8YFLogxK

U2 - 10.1124/dmd.105.006551

DO - 10.1124/dmd.105.006551

M3 - Article

VL - 34

SP - 361

EP - 368

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 3

ER -